

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants:

James L. Sackrison et al.

Attorney Docket: DIA1001US

Serial No:

10/706,567

Filed:

November 12, 2003

For:

VITAMIN D ASSAY

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22323-1450

Dear Sir:

Pursuant to Sections 1.56, 1.97, and 1.98 of Title 37 of the Code of Federal Regulations, the following information is set forth in compliance with Applicants' duty of disclosure, as well as the duty of others substantively involved in the preparation of the above-titled application.

The Applicants and others substantively involved in the preparation of the application are aware of the documents, listed on the enclosed PTO-1449 form, and have enclosed copies of the listed documents.

The present statement reflects the direct knowledge of the undersigned and information disclosed to the undersigned by the Applicants and others substantively involved in the preparation of the present application pursuant to their duty under 37 C.F.R. § 1.56.

Certificate of Express Mailing (37 C.F.R. § 1.10)

I hereby certify that this paper or fee is being deposited with the United States Postal Service as "Express Mail Post Office to Addressee" Mailing Label No. EV 398760718 US in an envelope addressed t: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 op the date indicated below.

Date: January 5, 2007

Signature:

Name: Jodi Jung

01-06-04

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

licants:

James L. Sackrison et al.

Attorney Docket: DIA1001US

Serial No:

10/706,567

Filed:

November 12, 2003

For:

VITAMIN D ASSAY

TRANSMITTAL LETTER

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

Transmitted herewith are the following:

- 1. Information Disclosure Statement (2 pages);
- 2. Form 1449 listing 10 documents (1 page, in duplicate); and
- 3. Copy of each of the listed documents.

Please charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 16-2312. A duplicate copy of this Transmittal Letter is enclosed for that purpose.

Dated: January 5, 2004

Respectfully submitted,

Ćustomer No. 009561

Patrick J. O'Connell, Esq. (33,984)

Miriam G. Simmons (34,727)

POPOVICH, WILES &

O'CONNELL, P.A.

650 Third Avenue North, Suite 600

Minneapolis, MN 55402 Telephone: (612) 334-8989

Representatives of Applicants

Certificate of Express Mailing (37 C.F.R. § 1.10)

I hereby certify that this paper or fee is being deposited with the United States Postal Service as "Express Mail Post Office to Addressee" Mailing Label No. EV 398760718 US in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 of the date indicated bel w.

Signature:

Name: Jode/Jung

Information Disclosure Statement Applicants: James L. Sackrison et al.

Serial Number: 10/706,567

Applicants reserve the right to show, pursuant to 37 C.F.R. § 1.131 or otherwise, that any one or more of the documents cited on the PTO-1449 form is not prior art to the present invention.

Pursuant to the Manual of Patent Examining Procedure, Chapter 609, Applicants request that the Examiner consider each of the listed documents and initial and return to the undersigned a copy of the enclosed PTO-1449 form (submitted in duplicate).

It is believed that no additional fees are due in connection with this submission. However if this is incorrect, please charge any additional fees to Deposit Account No. 16-2312.

Respectfully submitted,

Dated: January 5, 2004

Customer No. 009561

Patrick J. O'Connell, Esq. (33,984)

Attorney Docket: DIA1001US

Miriam G. Simmons (34,727)

POPOVICH, WILES &

O'CONNELL, P.A.

650 Third Avenue North, Suite 600

Minneapolis, MN 55402

Telephone: (612) 334-8989

Representatives of Applicants

						··							Shee	t <u>1</u> c	of 1
	FORM	PTO-	-1449	•					NT OF COMME ADEMARK OF		ATTY. DOCKET N	О.	SERIAL NO.		
	TPE				F#	VI CIN	I AN	אוט	ADEMARK OF	TICE	DIA1001US		10/706,567		
	O	~)				N DI					APPLICANTS				
	JAN 0 5 2004	الله الله	517	4 I E IV	/IEN I	BY	4PPL	.ICAN	41		James L. Sackriso	n et al.			
\	Jrus	E S	(Use	seve	ral sl	neets	if ne	cess	ary)		FILING DATE		GROUP ART	UNIT	
Z	WIGHTE PLANS								· · · · · · · · · · · · · · · · · · ·		November 12, 200	3			
į									U.S. PAT	ENT	DOCUMENTS				
	EXAMINER INITIAL		DO	CUM	ENT	NUME	BER		DATE		NAME	CLASS	SUBCLASS	FILING I	DATE IF PRIATE
		3	9	1	1	0	9	6	10/07/75	Cho	opra				
•		5	8	2	1	0	2	0	10/13/98	Hol	lis				
					<u> </u>										
										ļ					
							_								
			<u> </u>												
								F	OREIGN P	ATE	NT DOCUMEN	ΓS			
			DO	СПМ	ENT	NUME	BER		DATE		COUNTRY	CLASS	SUBCLASS	TRANSL YES	ATION NO
		EP	0 5	83 9	945 /	42			02/23/94	EPO)	1			
		EP	0 5	83 9	45 /	43			02/23/94	EPO)				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

EXAMINER	DATE CONSIDERED
	Trends," <u>J. Pharm. Biomed. Anal.</u> , 20:1-17 (1999).
	Luque de Castro et al., "Determination of Vitamin D ₃ Metabolites: State-of-the-Art and
	Lind et al., "Enzyme Immunoassay for Measuring 25-Hydroxyvitamin D₃ in Serum," Clinical Chemistry, 43(6):943-949 (1997).
	Chromatography, 290:107-112 (1984)
	Chromatography and Modified Competitive Protein Binding Assay," <u>Journal of</u>
	Justova et al., "Determination of 1,25-Dihydroxyvitamin D ₃ in Plasma Using Thin-Layer
	Human Plasma," <u>Journal of Chromatography</u> , 343:43-49 (1985).
	Hollis et al., "Solid Phase Extraction System for Vitamin D and Its Major Metabolites in
	Press, San Diego, 1997, pp. 587-606.
	Hollis, "Detection of Vitamin D and Its Major Metabolites," in Vitamin D, Academic
	1661 (2000).
	Determination of Circulating 25-Hydroxyvitamin D," Clinical Chemistry, 46(10):1657-
	Hollis, "Comparison of Commercially Available ' ² I-based RIA Methods for the

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

													Shee	t _ 1_of _ 1
	FORM	PTO	-1449)					NT OF COMMI		ATTY. DOCKET NO	D.	SERIAL NO.	
	TPE				PA	TEN	T AN	D TR	ADEMARK OF	FICE	DIA1001US		10/706,567	
/ `	` ` '		INF	ORM	ATIC	N DI	SCL	OSUF	RE		APPLICANTS		10/100,001	
'	AN 0'5 2004	2	STA	ATEM	IENT	BY	APPL	ICAN	IT .					
		الخ	(Use	seve	ral si	heets	if ne	cess	arv)		James L. Sackrisor FILING DATE	et al.	GROUP ART	LINIT
1	b at	} /	,000					0000	<u>,,,</u>				0.000. 70	OM
	TO TRADEMARK	···									November 12, 2003	3		
į									U.S. PAT	ENT	DOCUMENTS			
	EXAMINER INITIAL		DO	CUM	ENT I	NUME	BER		DATE		NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	·	3	9	1	1	0	9	6	10/07/75	Cho	opra			
÷		5	8	2	1	0	2	0	10/13/98	Hol	lis			
			1											
													1	
											<u>. </u>		<u> </u>	
				<u> </u>					! !	<u></u>				
								F	OREIGN P	ATE	NT DOCUMENT	S		
			DO	CUM	ENT I	NUME	BER		DATE		COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

EPO

EPO

02/23/94

02/23/94

Hollis, "Comparison of Commercially Available ¹²⁵ I-based RIA Methods for the Determination of Circulating 25-Hydroxyvitamin D," <u>Clinical Chemistry</u> , 46(10):1657-1661 (2000).
Hollis, "Detection of Vitamin D and Its Major Metabolites," in <u>Vitamin D</u> , Academic Press, San Diego, 1997, pp. 587-606.
Hollis et al., "Solid Phase Extraction System for Vitamin D and Its Major Metabolites in Human Plasma," Journal of Chromatography, 343:43-49 (1985).
Justova et al., "Determination of 1,25-Dihydroxyvitamin D ₃ in Plasma Using Thin-Layer Chromatography and Modified Competitive Protein Binding Assay," <u>Journal of Chromatography</u> , 290:107-112 (1984)
Lind et al., "Enzyme Immunoassay for Measuring 25-Hydroxyvitamin D₃ in Serum," Clinical Chemistry, 43(6):943-949 (1997).
Luque de Castro et al., "Determination of Vitamin D ₃ Metabolites: State-of-the-Art and Trends," <u>J. Pharm. Biomed. Anal.</u> , 20:1-17 (1999).

EXAMINER

EP 0 583 945 A2

EP 0 583 945 A3

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.